Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

DUSP1 (dual specificity phosphatase 1)

Written2012-05Mark Kristiansen
Molecular Haematology, Cancer Biology Unit, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK

(Note : for Links provided by Atlas : click)


Alias_symbol (synonym)HVH1
Other aliasMKP1
LocusID (NCBI) 1843
Atlas_Id 40371
Location 5q35.1  [Link to chromosome band 5q35]
Location_base_pair Starts at 172768090 and ends at 172771200 bp from pter ( according to hg19-Feb_2009)  [Mapping DUSP1.png]
Local_order The DUSP1 gene is flanked by the gene ERGIC1 (upstream) and the NEURL1B gene (downstream) in the plus strand direction according to Ensembl annotation.
  Figure 1. Genomic context of the human DUSP1 gene. Figure 1 shows the location of DUSP1 on chromosome 5 which is located between the NEURL1B and ERGIC1 genes. Arrows indicate the 5' to 3' orientation of each gene. Adapted from the NCBI Map Viewer.
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
ARFIP1 (4q31.3) / DUSP1 (5q35.1)CCDC69 (5q33.1) / DUSP1 (5q35.1)DUSP1 (5q35.1) / DUSP1 (5q35.1)
DUSP1 (5q35.1) / GLI3 (7p14.1)DUSP1 (5q35.1) / MFN1 (3q26.33)DUSP1 (5q35.1) / ST5 (11p15.4)
KIF1B (1p36.22) / DUSP1 (5q35.1)
Note DUSP1 is a MAPK phosphatase and is a member of the subfamily of dual specificity phosphatases (DUSPs). These phosphatases can inactivate MAP kinases by dephosphorylating both phospho-threonine and phospho-tyrosine residues located in the activation loop. DUSP1 is the canonical MAPK phosphatase and is an immediate early gene. DUSP1 mRNA levels increase in response to many factors depending on the cell type, including heat shock and oxidative stress (Keyse and Emslie, 1992; Franklin et al., 1998), UV light (Franklin et al., 1998), and survival factor withdrawal (Kristiansen et al., 2010). DUSP1 knockout mice have no overt phenotype from histology to behaviour.


Note The human DUSP1 gene spans 3111 bases, telomere to centromere orientation.
  Figure 2. Structure of the human DUSP1 gene and its variants. The full length human DUSP1 transcript (Variant1) is 2019 nucleotides long and consists of four exons separated by three introns of 400-500 bp. The DUSP1 gene is approximately 3.8 kb from the putative transcription initiation site to the end of exon 4. The 5' untranslated region (5' UTR) and the putative translational start site (ATG) can be found in exon 1. The non-catalytic region homologous to Cdc25, also known as the CH2 domain, is represented by the blue regions and is found in exons 1 and 2. Exon 4 contains the sequence encoding the active site cysteine for PTPase activity (orange region) and also contains > 660 nt of 3' UTR and the polyadenylation signal (AATAA). According to Ensembl, there are two other DUSP1 variants with transcript lengths of 1394 bp (Variant2) and 1854 bp (Variant3).
Figure 3. Alignment of the promoter sequences for the rat and human DUSP1 genes. There are two conserved, potential ATF binding sites in the DUSP1 promoter. ATF site 1 is located at position 172 to 165 in relation to the transcriptional start site and is one base different from the ATF/CRE consensus site. ATF site 2, is located at position 124 to 117 and is an exact match for the ATF/CRE consensus site. A TATA box and a conserved E box are also highlighted. * represent bases conserved between the human and rat gene. The transcriptional start site of the DUSP1 gene in each species is indicated by an arrow. Adapted from Kristiansen et al., 2010.
Description The human DUSP1 gene is located on chromosome 5q35.1 and consists of 4 exons separated by three relatively small introns (400-500 bp) (Figure 2). The full length coding sequence of DUSP1 contains 2019 nucleotides. The human DUSP1 gene contains four exons and three introns coding for an inducible mRNA with an approximate size of 2.4 kb (Kwak et al., 1994). The first domain which is located towards the C-terminus (Exon 4) contains the active site motif common to all PTPases, and the second domain (termed CH2) resides at the N-terminus (exons 1-2) and exhibits two segments of similarity to the region surrounding the Cdc25 active site.
Transcription Studies using northern blots have shown that high levels of DUSP1 mRNA were detected in lung, liver, placenta, and pancreas whereas moderate levels of DUSP1 mRNA were found in the heart and skeletal muscle (Kwak et al., 1994). Low levels were detected in the brain and kidney. Nevertheless, an abundance of factors can upregulate DUSP1 mRNA levels in a variety of cell types. DUSP1 is a transcriptional target of p53 which binds to the p53 binding site located in the second intron which was first shown in a human glioblastoma cell line (Li et al., 2003). DUSP1 is also upregulated in response to a variety of cellular stress conditions including oxidative stress and DNA damaging agents in human skin cells (Keyse and Emslie, 1992). DUSP1 mRNA is also upregulated in response to hypoxia at levels found in solid tumours (Laderoute et al., 1999). A strong induction of the DUSP1 gene was seen in neuroendocrine cells by thyrotropin-releasing hormone (TRH) and epidermal growth factor (EGF) (Ryser et al., 2001; Ryser et al., 2002).
The initial 1 kb region upstream of exon 1 in the DUSP1 promoter contains elements important for the control of DUSP1 transcription (Figure 3). However, as well as a TATA box, an E-box and 2 conserved and functionally important ATF binding sites, this region also contains three GC boxes and an NF1 site (Kwak et al., 1994; Pursiheimo et al., 2002; Ryser et al., 2004; Kristiansen et al., 2010). The two ATF sites have been shown to bind c-Jun and ATF2 which is important for the activation of DUSP1 transcription by the JNK pathway following survival factor withdrawal in neurons (Kristiansen et al., 2010).
Pseudogene There are no known pseudogenes for DUSP1.


  Figure 4. The structural features of the DUSP1 protein. The highly conserved C-terminal domain of DUSP1 contains the catalytic and stabilisation and destabilisation domains of the protein. The catalytic domain contains the active site sequence for the dephosphorylation of tyrosine/threonine residues of target substrates. The N-terminal domain of DUSP1 is mainly responsible for nuclear localisation through its leucine-rich nuclear targeting sequence (LXXLL) (Wu et al., 2005) and the binding of MAPK through its specific arginine-rich kinase binding domain. According to UniProtKB/Swiss-Prot, the catalytically inactive rhodanese domain is located within residues 20-137.
Description DUSP family members share a common structure comprising a C-terminal cysteine-dependent protein tyrosine phosphatase active site sequence (Camps et al., 2000). The structure of DUSP proteins confers phosphatase activity for both phospho-serine/threonine and phospho-tyrosine residues. The non-catalytic N-terminal region contains a rhodanese domain which is known to catalyse a sulphur transfer reaction. Also in this domain are two regions of homology with sequences flanking the active site of the Cdc25 cell cycle regulatory phosphatase (Keyse and Ginsberg, 1993). The full-length human DUSP1 protein (Transcript variant 1) contains 367 amino acids and has a molecular weight of 39 kDa (Figure 4). Two further transcripts have been described. Transcript variant 2 codes for a shorter protein of 302 amino acids with a molecular weight of 32 kDa. Transcript variant 3 encodes for a protein of 340 amino acids with a molecular weight of 36 kDa.
Expression Increases in DUSP1 protein expression have been seen in a variety of cell types in response to various signals (Table 1) such as EGF-treated mouse embryonic fibroblasts (Wu and Bennett, 2005) and NGF-deprived rat sympathetic neurons (Kristiansen et al., 2010). The half life of DUSP1 has been found to vary between 40 and 120 minutes (Charles et al., 1992; Noguchi et al., 1993).
  Table 1. Regulation of DUSP1 expression levels. Table 1 shows a some examples of how DUSP1 protein expression levels can be increased in a range of cell types in response to various signals.
Localisation DUSP1 is primarily a nuclear dual specificity protein phosphatase.
Function Mitogen activated protein kinases (MAPK) are a family of kinases that include the extracellular signal regulated kinases (ERKs), p38 and c-Jun NH2-terminal kinase (JNKs). They play an important role in regulation and are activated by a number of stimuli such as growth factors, cytokines or stress conditions. This in turn regulates a variety of processes including proliferation, apoptosis, survival and the production of inflammatory molecules. As a result the regulation of MAPKs is important and so an equilibrium between the activation of MAPKs and their deactivation is vital.
Dual-specificity phosphatases (DUSP) are a large family of phosphatases that include the subset of MAPK phosphatases (MKPs). In particular, DUSP1 is a nuclear mitogen-activated protein kinase (MAPK) phosphatase with substrate specificity for p38 kinases and JNKs and to a lesser extent ERK (Franklin and Kraft, 1997; Camps et al., 2000; Farooq and Zhou, 2004) and functions by dephosphorylating the phospho-threonine and phospho-tyrosine residues located in the activation loop of their target substrates (Patterson et al., 2009) to negatively regulate MAPK signalling (Sun et al., 1993; Keyse, 2000; Kristiansen et al., 2010).
DUSP1 is a negative regulator of cellular proliferation but also has other functions such as the regulation of cytokine biosynthesis in response to bacterial lipopolysaccharide (LPS) (Huang et al., 2011). DUSP1 plays a significant role in immune regulation (reviewed in Wancket et al., 2012) and it has been shown that the half lives of several cytokines can be reduced by the overexpression of DUSP1 mRNA (Yu et al., 2011a). DUSP1 has also been shown to play a part in mediating the anti-inflammatory response to glucocorticoids (Chi et al., 2006; Hammer et al., 2005; Abraham et al., 2006; Zhao et al., 2006). DUSP1 has an important role in metabolic homeostasis, as studies have shown that mice lacking the DUSP1 gene are resistant to obesity induced by a high fat diet (Zhang et al., 2004). Furthermore, DUSP1 can play a role in altering lipid metabolism in multiple tissues when a high fat diet is consumed (Flach et al, 2011; Wu et al., 2006). DUSP1 protects mice from lethal endotoxic shock (Hammer et al., 2006) and it has also been shown that DUSP1 can protect the oral cavity against inflammation triggered by bacterial ligands (Sartori et al., 2009; Yu et al., 2011b). In rodent stroke models, DUSP1 overexpression has been shown to suppress neuronal death in a negative feedback manner (Koga et al., 2012).
Homology DUSPs contain two regions of homology with the cell cycle regulatory phosphatase Cdc25 in their NH2-terminal domain. A conserved catalytic domain in the C-terminal region, contains an active site with a sequence related to the VH-1 DUSP encoded by the vaccina virus. A kinase interactive motif (KIM) also resides in the NH2 terminal domain. This conserved cluster of basic amino acids distinguishes the specificity of MPKs for their MAPK targets. A localisation sequence is also found in the NH2 terminal domain and this determines their cellular localisation. These differences give rise to three groups based on their sequence similarity, structure, substrate specificity and localisation. DUSP1 along with DUSP2, DUSP4 and DUSP5 are known as inducible nuclear phosphatases (Keyse, 2008). DUSP6, DUSP7 and DUSP9 are the closely related ERK-specific and cytoplasmic MKPs whilst DUSP8, DUSP10 and DUSP16 preferentially inactivate p38 and JNK MAP kinases (Keyse, 2008).


Note A SNP in the DUSP1 gene was identified in intron 1 in a Japanese subpopulation but because this polymorphic site is not within a coding region, it is not likely to influence the function of the gene product (Suzuki et al., 2001).

Implicated in

Entity Various cancers
Note MAP kinase activities impinge on many of the processes involved in the initiation and genesis of cancer and therefore abnormalities in MAPK signalling pathways have been implicated in a wide range of human malignancies, such as cancer of the colon, prostate, bladder, ovary, breast and also in NSCLC. DUSP1 has conflicting roles depending upon the level of its expression which has been seen to be increased in early stages of cancer of the prostate, bladder and colon but whose level decreases at later stages. Conversely, downregulation of DUSP1 could increase apoptosis. Pharmacological targeting of DUSP1 could be considered as a useful tool for improving cancer treatments and maintaining metabolic homeostasis (Flach et al., 2012).
Entity Human epithelial tumours
Note In human epithelial tumours (colon, bladder and prostate), early studies have shown an increase in the DUSP1 mRNA in the early stages of the disease (Loda et al., 1996). Interestingly, DUSP1 mRNA overexpression falls as the tumour becomes more aggressive and hence with disease progression and was confirmed in transcriptional profiling studies (Zhang et al., 1997).
In prostate cancer an increase in DUSP1 levels showed inverse correlation with JNK activity and apoptotic markers suggesting that DUSP1 could be anti-apoptotic (Magi-Galuzzi et al., 1997; Magi-Galuzzi et al., 1998). Furthermore, human prostate cancer cells overexpressing DUSP1 are resistant to apoptosis induced by Fas-ligand (Srikanth et al., 1999).
Entity Ovarian cancer
Note Varying levels of DUSP1 protein expression have been seen in a range of models of ovarian cancer. In low grade malignant tumours, the level of DUSP1 protein expression was reduced when compared with benign cysts and normal surface epithelium. Conversely, in primary ovarian tumours, moderate to strong expression of DUSP1 was detected in almost 60% of invasive ovarian cancers and there was a significant correlation between DUSP1 expression and a shorter progressive free survival (Denkert et al., 2002).
Entity Breast cancer
Note Studies have shown an increase in DUSP1 expression in the late stages of breast cancer (Loda et al., 1996). The high levels of DUSP1 correlated with a reduction in JNK activity. This could mean that therapeutically targeting DUSP1 would increase JNK activity and hence pro-apoptotic signals in malignant cells (Wang et al., 2003). Studies show that DUSP1 overexpression decreases JNK activity whilst DUSP1 knockdown using siRNA enhanced JNK activity (Small et al., 2007). Recently, it has been shown in human T47D breast cancer cells that DUSP1 is a target gene for Progesterone Receptor (PR) and may have a role in its anti-proliferative and anti-inflammatory actions (Chen et al., 2011).
Entity Non-small cell lung cancer (NSCLC)
Note In NSCLC, DUSP1 protein levels are increased (Vicent et al., 2004; Lim et al., 2003). The localisation of DUSP1 is predominantly in the nucleus in NSCLC tumour tissue compared to normal bronchial epithelium where the protein is localised in both the cytoplasm and the nucleus. DUSP1 overexpression increased resistance to cisplatin, a drug which can be used to treat the disease (Wang et al., 2006).
Entity Other cancers
Note An increase in the level of DUSP1 protein has also been shown in gastric adenocarcinoma (Bang et al., 1998). In nude mice, downregulation of DUSP1 expression leads to a reduction of tumorigenicity of pancreatic cancer cells (Liao et al., 2003). Interestingly, in hepatocellular carcinoma, DUSP1 levels are decreased which could suggest an opposite role for DUSP1 in tumour progression (Tsujita et al., 2005). In lung squamous cell carcinoma (SCC), it has been reported that levels of DUSP1 expression decrease with cancer progression (Wang et al., 2011). DUSP1 is upregulated by hypoxia, which is seen in many grown tumours (Brahimi-Horn et al., 2007).


Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1.
Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, Clark AR.
J Exp Med. 2006 Aug 7;203(8):1883-9. Epub 2006 Jul 31.
PMID 16880258
Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma.
Bang YJ, Kwon JH, Kang SH, Kim JW, Yang YC.
Biochem Biophys Res Commun. 1998 Sep 8;250(1):43-7.
PMID 9735328
Hypoxia and cancer.
Brahimi-Horn MC, Chiche J, Pouyssegur J.
J Mol Med (Berl). 2007 Dec;85(12):1301-7. Epub 2007 Nov 20. (REVIEW)
PMID 18026916
MAPK phosphatase-1 (MKP-1) expression is up-regulated by hCG/cAMP and modulates steroidogenesis in MA-10 Leydig cells.
Brion L, Maloberti PM, Gomez NV, Poderoso C, Gorostizaga AB, Mori Sequeiros Garcia MM, Acquier AB, Cooke M, Mendez CF, Podesta EJ, Paz C.
Endocrinology. 2011 Jul;152(7):2665-77. Epub 2011 May 10.
PMID 21558315
Dual specificity phosphatases: a gene family for control of MAP kinase function.
Camps M, Nichols A, Arkinstall S.
FASEB J. 2000 Jan;14(1):6-16. (REVIEW)
PMID 10627275
cDNA sequence of a growth factor-inducible immediate early gene and characterization of its encoded protein.
Charles CH, Abler AS, Lau LF.
Oncogene. 1992 Jan;7(1):187-90.
PMID 1741163
Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1).
Chen CC, Hardy DB, Mendelson CR.
J Biol Chem. 2011 Dec 16;286(50):43091-102. Epub 2011 Oct 21.
PMID 22020934
Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses.
Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, Flavell RA.
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2274-9. Epub 2006 Feb 6.
PMID 16461893
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.
Denkert C, Schmitt WD, Berger S, Reles A, Pest S, Siegert A, Lichtenegger W, Dietel M, Hauptmann S.
Int J Cancer. 2002 Dec 10;102(5):507-13.
PMID 12432554
Structure and regulation of MAPK phosphatases.
Farooq A, Zhou MM.
Cell Signal. 2004 Jul;16(7):769-79. (REVIEW)
PMID 15115656
Loss of mitogen-activated protein kinase phosphatase-1 protects from hepatic steatosis by repression of cell death-inducing DNA fragmentation factor A (DFFA)-like effector C (CIDEC)/fat-specific protein 27.
Flach RJ, Qin H, Zhang L, Bennett AM.
J Biol Chem. 2011 Jun 24;286(25):22195-202. Epub 2011 Apr 26.
PMID 21521693
Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis.
Franklin CC, Srikanth S, Kraft AS.
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3014-9.
PMID 9501207
Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation.
Furst R, Brueckl C, Kuebler WM, Zahler S, Krotz F, Gorlach A, Vollmar AM, Kiemer AK.
Circ Res. 2005 Jan 7;96(1):43-53. Epub 2004 Nov 29.
PMID 15569826
Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock.
Hammer M, Mages J, Dietrich H, Servatius A, Howells N, Cato AC, Lang R.
J Exp Med. 2006 Jan 23;203(1):15-20. Epub 2005 Dec 27.
PMID 16380512
Signaling by the phosphatase MKP-1 in dendritic cells imprints distinct effector and regulatory T cell fates.
Huang G, Wang Y, Shi LZ, Kanneganti TD, Chi H.
Immunity. 2011 Jul 22;35(1):45-58. Epub 2011 Jun 30.
PMID 21723158
Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase.
Keyse SM, Emslie EA.
Nature. 1992 Oct 15;359(6396):644-7.
PMID 1406996
Amino acid sequence similarity between CL100, a dual-specificity MAP kinase phosphatase and cdc25.
Keyse SM, Ginsburg M.
Trends Biochem Sci. 1993 Oct;18(10):377-8. (REVIEW)
PMID 8256285
Dual-specificity MAP kinase phosphatases (MKPs) and cancer.
Keyse SM.
Cancer Metastasis Rev. 2008 Jun;27(2):253-61. (REVIEW)
PMID 18330678
Over-expression of map kinase phosphatase-1 (MKP-1) suppresses neuronal death through regulating JNK signaling in hypoxia/re-oxygenation.
Koga S, Kojima S, Kishimoto T, Kuwabara S, Yamaguchi A.
Brain Res. 2012 Feb 3;1436:137-46. Epub 2011 Dec 8.
PMID 22197701
Mkp1 is a c-Jun target gene that antagonizes JNK-dependent apoptosis in sympathetic neurons.
Kristiansen M, Hughes R, Patel P, Jacques TS, Clark AR, Ham J.
J Neurosci. 2010 Aug 11;30(32):10820-32.
PMID 20702711
Isolation and characterization of a human dual specificity protein-tyrosine phosphatase gene.
Kwak SP, Hakes DJ, Martell KJ, Dixon JE.
J Biol Chem. 1994 Feb 4;269(5):3596-604.
PMID 8106404
Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity.
Laderoute KR, Mendonca HL, Calaoagan JM, Knapp AM, Giaccia AJ, Stork PJ.
J Biol Chem. 1999 Apr 30;274(18):12890-7.
PMID 10212278
The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation.
Li M, Zhou JY, Ge Y, Matherly LH, Wu GS.
J Biol Chem. 2003 Oct 17;278(42):41059-68. Epub 2003 Jul 29.
PMID 12890671
Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.
Liao Q, Guo J, Kleeff J, Zimmermann A, Buchler MW, Korc M, Friess H.
Gastroenterology. 2003 Jun;124(7):1830-45.
PMID 12806617
Feasibility of using low-volume tissue samples for gene expression profiling of advanced non-small cell lung cancers.
Lim EH, Aggarwal A, Agasthian T, Wong PS, Tan C, Sim E, Tan L, Goh PS, Wang SC, Khoo KL, Mukherjee A, Khoo SM, Chua G, Nilsson B, Lee KH, Tan P.
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5980-7.
PMID 14676123
Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK.
Liu C, Shi Y, Du Y, Ning X, Liu N, Huang D, Liang J, Xue Y, Fan D.
Exp Cell Res. 2005 Oct 1;309(2):410-8.
PMID 16081065
Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.
Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, Stork PJ.
Am J Pathol. 1996 Nov;149(5):1553-64.
PMID 8909245
Osmotic regulation of insulin-induced mitogen-activated protein kinase phosphatase (MKP-1) expression in H4IIE rat hepatoma cells.
Lornejad-Schafer MR, Schafer C, Graf D, Haussinger D, Schliess F.
Biochem J. 2003 Apr 15;371(Pt 2):609-19.
PMID 12529177
Mitogen-activated protein kinases and apoptosis in PIN.
Magi-Galluzzi C, Montironi R, Cangi MG, Wishnow K, Loda M.
Virchows Arch. 1998 May;432(5):407-13.
PMID 9645439
Induction of mitogen-activated protein kinase phosphatase-1 by arachidonic acid in vascular smooth muscle cells.
Metzler B, Hu Y, Sturm G, Wick G, Xu Q.
J Biol Chem. 1998 Dec 11;273(50):33320-6.
PMID 9837905
Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth.
Noguchi T, Metz R, Chen L, Mattei MG, Carrasco D, Bravo R.
Mol Cell Biol. 1993 Sep;13(9):5195-205.
PMID 8355678
Dual-specificity phosphatases: critical regulators with diverse cellular targets.
Patterson KI, Brummer T, O'Brien PM, Daly RJ.
Biochem J. 2009 Mar 15;418(3):475-89. (REVIEW)
PMID 19228121
Protein kinase A balances the growth factor-induced Ras/ERK signaling.
Pursiheimo JP, Kieksi A, Jalkanen M, Salmivirta M.
FEBS Lett. 2002 Jun 19;521(1-3):157-64.
PMID 12067709
Stimulated initiation of mitogen-activated protein kinase phosphatase-1 (MKP-1) gene transcription involves the synergistic action of multiple cis-acting elements in the proximal promoter.
Ryser S, Massiha A, Piuz I, Schlegel W.
Biochem J. 2004 Mar 1;378(Pt 2):473-84.
PMID 14609431
Map kinase phosphatase-1 gene expression and regulation in neuroendocrine cells.
Ryser S, Tortola S, Schlegel W.
J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):17-29.
PMID 12503606
MAP kinase phosphatase-1 protects against inflammatory bone loss.
Sartori R, Li F, Kirkwood KL.
J Dent Res. 2009 Dec;88(12):1125-30. Epub 2009 Oct 28.
PMID 19864641
Glucagon-induced expression of the MAP kinase phosphatase MKP-1 in rat hepatocytes.
Schliess F, Kurz AK, Haussinger D.
Gastroenterology. 2000 May;118(5):929-36.
PMID 10784592
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis.
Seta KA, Kim R, Kim HW, Millhorn DE, Beitner-Johnson D.
J Biol Chem. 2001 Nov 30;276(48):44405-12. Epub 2001 Sep 27.
PMID 11577072
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
Small GW, Shi YY, Higgins LS, Orlowski RZ.
Cancer Res. 2007 May 1;67(9):4459-66.
PMID 17483361
Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis.
Srikanth S, Franklin CC, Duke RC, Kraft RS.
Mol Cell Biochem. 1999 Sep;199(1-2):169-78.
PMID 10544965
MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo.
Sun H, Charles CH, Lau LF, Tonks NK.
Cell. 1993 Nov 5;75(3):487-93.
PMID 8221888
Identification and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes.
Suzuki C, Unoki M, Nakamura Y.
J Hum Genet. 2001;46(3):155-7.
PMID 11310585
High glucose attenuates insulin-induced mitogen-activated protein kinase phosphatase-1 (MKP-1) expression in vascular smooth muscle cells.
Takehara N, Kawabe J, Aizawa Y, Hasebe N, Kikuchi K.
Biochim Biophys Acta. 2000 Jul 21;1497(2):244-52.
PMID 10903429
Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma.
Tsujita E, Taketomi A, Gion T, Kuroda Y, Endo K, Watanabe A, Nakashima H, Aishima S, Kohnoe S, Maehara Y.
Oncology. 2005;69(4):342-7. Epub 2005 Nov 16.
PMID 16293973
Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
Vicent S, Garayoa M, Lopez-Picazo JM, Lozano MD, Toledo G, Thunnissen FB, Manzano RG, Montuenga LM.
Clin Cancer Res. 2004 Jun 1;10(11):3639-49.
PMID 15173070
Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease.
Wancket LM, Frazier WJ, Liu Y.
Life Sci. 2012 Feb 13;90(7-8):237-48. Epub 2011 Dec 13. (REVIEW)
PMID 22197448
Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer.
Wang HY, Cheng Z, Malbon CC.
Cancer Lett. 2003 Mar 10;191(2):229-37.
PMID 12618338
Imbalanced expression of mitogen-activated protein kinase phosphatase-1 and phosphorylated extracellular signal-regulated kinases in lung squamous cell carcinoma.
Wang K, Zhang M, Qian YY, Ding ZY, Lv JH, Shen HH.
J Zhejiang Univ Sci B. 2011 Oct;12(10):828-34.
PMID 21960346
Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance.
Wang Z, Xu J, Zhou JY, Liu Y, Wu GS.
Cancer Res. 2006 Sep 1;66(17):8870-7.
PMID 16951204
Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling.
Wu JJ, Bennett AM.
J Biol Chem. 2005 Apr 22;280(16):16461-6. Epub 2005 Feb 17.
PMID 15722358
Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity.
Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee MK, Choi CS, Neufer PD, Shulman GI, Kim JK, Bennett AM.
Cell Metab. 2006 Jul;4(1):61-73.
PMID 16814733
The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation.
Wu JJ, Zhang L, Bennett AM.
Mol Cell Biol. 2005 Jun;25(11):4792-803.
PMID 15899879
Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells.
Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD.
Cancer Res. 2004 Mar 1;64(5):1757-64.
PMID 14996737
Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.
Wu W, Pew T, Zou M, Pang D, Conzen SD.
J Biol Chem. 2005 Feb 11;280(6):4117-24. Epub 2004 Dec 7.
PMID 15590693
Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss.
Yu H, Li Q, Herbert B, Zinna R, Martin K, Junior CR, Kirkwood KL.
Gene Ther. 2011b Apr;18(4):344-53. Epub 2010 Nov 11.
PMID 21068780
MKP-1 regulates cytokine mRNA stability through selectively modulation subcellular translocation of AUF1.
Yu H, Sun Y, Haycraft C, Palanisamy V, Kirkwood KL.
Cytokine. 2011a Nov;56(2):245-55. Epub 2011 Jul 5.
PMID 21733716
Parathyroid hormone-related protein induces insulin expression through activation of MAP kinase-specific phosphatase-1 that dephosphorylates c-Jun NH2-terminal kinase in pancreatic beta-cells.
Zhang B, Hosaka M, Sawada Y, Torii S, Mizutani S, Ogata M, Izumi T, Takeuchi T.
Diabetes. 2003 Nov;52(11):2720-30.
PMID 14578290
Gene expression profiles in normal and cancer cells.
Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW.
Science. 1997 May 23;276(5316):1268-72.
PMID 9157888
MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock.
Zhao Q, Wang X, Nelin LD, Yao Y, Matta R, Manson ME, Baliga RS, Meng X, Smith CV, Bauer JA, Chang CH, Liu Y.
J Exp Med. 2006 Jan 23;203(1):131-40. Epub 2005 Dec 27.
PMID 16380513


This paper should be referenced as such :
Kristiansen, M
DUSP1 (dual specificity phosphatase 1)
Atlas Genet Cytogenet Oncol Haematol. 2012;16(11):789-795.
Free journal version : [ pdf ]   [ DOI ]
On line version :

Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 1 ]
  t(3;5)(q26;q35) DUSP1/MFN1

External links

HGNC (Hugo)DUSP1   3064
Entrez_Gene (NCBI)DUSP1  1843  dual specificity phosphatase 1
AliasesCL100; HVH1; MKP-1; MKP1; 
GeneCards (Weizmann)DUSP1
Ensembl hg19 (Hinxton)ENSG00000120129 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000120129 [Gene_View]  ENSG00000120129 [Sequence]  chr5:172768090-172771200 [Contig_View]  DUSP1 [Vega]
ICGC DataPortalENSG00000120129
TCGA cBioPortalDUSP1
Genatlas (Paris)DUSP1
SOURCE (Princeton)DUSP1
Genetics Home Reference (NIH)DUSP1
Genomic and cartography
GoldenPath hg38 (UCSC)DUSP1  -     chr5:172768090-172771200 -  5q35.1   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)DUSP1  -     5q35.1   [Description]    (hg19-Feb_2009)
GoldenPathDUSP1 - 5q35.1 [CytoView hg19]  DUSP1 - 5q35.1 [CytoView hg38]
Mapping of homologs : NCBIDUSP1 [Mapview hg19]  DUSP1 [Mapview hg38]
Gene and transcription
Genbank (Entrez)AA843403 AJ227912 AK298047 AK298658 AK299391
RefSeq transcript (Entrez)NM_004417
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)DUSP1
Cluster EST : UnigeneHs.171695 [ NCBI ]
CGAP (NCI)Hs.171695
Alternative Splicing GalleryENSG00000120129
Gene ExpressionDUSP1 [ NCBI-GEO ]   DUSP1 [ EBI - ARRAY_EXPRESS ]   DUSP1 [ SEEK ]   DUSP1 [ MEM ]
Gene Expression Viewer (FireBrowse)DUSP1 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevestigatorExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)1843
GTEX Portal (Tissue expression)DUSP1
Human Protein AtlasENSG00000120129-DUSP1 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP28562   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP28562  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP28562
Splice isoforms : SwissVarP28562
Domaine pattern : Prosite (Expaxy)RHODANESE_3 (PS50206)    TYR_PHOSPHATASE_1 (PS00383)    TYR_PHOSPHATASE_2 (PS50056)    TYR_PHOSPHATASE_DUAL (PS50054)   
Domains : Interpro (EBI)Atypical_DUSP    Dual-sp_phosphatase_cat-dom    DUSP    MKP    Prot-tyrosine_phosphatase-like    Rhodanese-like_dom    Rhodanese-like_dom_sf    Tyr_Pase_AS    Tyr_Pase_cat    TYR_PHOSPHATASE_dom    TYR_PHOSPHATASE_DUAL_dom   
Domain families : Pfam (Sanger)DSPc (PF00782)    Rhodanese (PF00581)   
Domain families : Pfam (NCBI)pfam00782    pfam00581   
Domain families : Smart (EMBL)DSPc (SM00195)  PTPc_motif (SM00404)  RHOD (SM00450)  
Conserved Domain (NCBI)DUSP1
DMDM Disease mutations1843
Blocks (Seattle)DUSP1
PDB Europe6APX   
Structural Biology KnowledgeBase6APX   
SCOP (Structural Classification of Proteins)6APX   
CATH (Classification of proteins structures)6APX   
Human Protein Atlas [tissue]ENSG00000120129-DUSP1 [tissue]
Peptide AtlasP28562
IPIIPI00003928   IPI00909460   IPI00942094   IPI00922849   
Protein Interaction databases
IntAct (EBI)P28562
Ontologies - Pathways
Ontology : AmiGOinactivation of MAPK activity  inactivation of MAPK activity  protein serine/threonine phosphatase activity  protein tyrosine phosphatase activity  protein binding  nucleus  nucleus  cytoplasm  cytoplasm  negative regulation of cell adhesion  protein tyrosine/serine/threonine phosphatase activity  protein tyrosine/serine/threonine phosphatase activity  negative regulation of cell proliferation  protein tyrosine/threonine phosphatase activity  response to light stimulus  MAP kinase tyrosine/serine/threonine phosphatase activity  MAP kinase tyrosine/serine/threonine phosphatase activity  growth factor binding  response to estradiol  response to retinoic acid  cellular response to hormone stimulus  response to testosterone  peptidyl-tyrosine dephosphorylation  peptidyl-tyrosine dephosphorylation  intracellular signal transduction  peptidyl-threonine dephosphorylation  response to hydrogen peroxide  positive regulation of apoptotic process  negative regulation of apoptotic process  negative regulation of MAP kinase activity  negative regulation of MAPK cascade  mitogen-activated protein kinase binding  response to glucocorticoid  negative regulation of meiotic cell cycle  response to cAMP  response to calcium ion  peptidyl-serine dephosphorylation  negative regulation of ERK1 and ERK2 cascade  mitotic cell cycle arrest  negative regulation of monocyte chemotaxis  regulation of mitotic cell cycle spindle assembly checkpoint  negative regulation of p38MAPK cascade  cellular response to chemokine  negative regulation of DNA biosynthetic process  
Ontology : EGO-EBIinactivation of MAPK activity  inactivation of MAPK activity  protein serine/threonine phosphatase activity  protein tyrosine phosphatase activity  protein binding  nucleus  nucleus  cytoplasm  cytoplasm  negative regulation of cell adhesion  protein tyrosine/serine/threonine phosphatase activity  protein tyrosine/serine/threonine phosphatase activity  negative regulation of cell proliferation  protein tyrosine/threonine phosphatase activity  response to light stimulus  MAP kinase tyrosine/serine/threonine phosphatase activity  MAP kinase tyrosine/serine/threonine phosphatase activity  growth factor binding  response to estradiol  response to retinoic acid  cellular response to hormone stimulus  response to testosterone  peptidyl-tyrosine dephosphorylation  peptidyl-tyrosine dephosphorylation  intracellular signal transduction  peptidyl-threonine dephosphorylation  response to hydrogen peroxide  positive regulation of apoptotic process  negative regulation of apoptotic process  negative regulation of MAP kinase activity  negative regulation of MAPK cascade  mitogen-activated protein kinase binding  response to glucocorticoid  negative regulation of meiotic cell cycle  response to cAMP  response to calcium ion  peptidyl-serine dephosphorylation  negative regulation of ERK1 and ERK2 cascade  mitotic cell cycle arrest  negative regulation of monocyte chemotaxis  regulation of mitotic cell cycle spindle assembly checkpoint  negative regulation of p38MAPK cascade  cellular response to chemokine  negative regulation of DNA biosynthetic process  
Pathways : KEGGMAPK signaling pathway    Serotonergic synapse   
REACTOMEP28562 [protein]
REACTOME PathwaysR-HSA-5675221 [pathway]   
NDEx NetworkDUSP1
Atlas of Cancer Signalling NetworkDUSP1
Wikipedia pathwaysDUSP1
Orthology - Evolution
GeneTree (enSembl)ENSG00000120129
Phylogenetic Trees/Animal Genes : TreeFamDUSP1
Homologs : HomoloGeneDUSP1
Homology/Alignments : Family Browser (UCSC)DUSP1
Gene fusions - Rearrangements
Fusion : MitelmanDUSP1/MFN1 [5q35.1/3q26.33]  
Fusion PortalDUSP1 5q35.1 MFN1 3q26.33 PRAD
Fusion : FusionGDB10702    10703    10704    10705    18830    2356    5888   
Fusion : Fusion_HubARFIP1--DUSP1    CCDC69--DUSP1    DUSP1--AAAS    DUSP1--ADRBK2    DUSP1--AGAP3    DUSP1--BASP1    DUSP1--C12ORF66    DUSP1--C16ORF58    DUSP1--CEBPD    DUSP1--CRNN    DUSP1--DUSP1    DUSP1--FLNC    DUSP1--GLI3    DUSP1--HBB    DUSP1--MFN1   
Fusion : QuiverDUSP1
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerDUSP1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)DUSP1
Exome Variant ServerDUSP1
ExAC (Exome Aggregation Consortium)ENSG00000120129
GNOMAD BrowserENSG00000120129
Varsome BrowserDUSP1
Genetic variants : HAPMAP1843
Genomic Variants (DGV)DUSP1 [DGVbeta]
DECIPHERDUSP1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisDUSP1 
ICGC Data PortalDUSP1 
TCGA Data PortalDUSP1 
Broad Tumor PortalDUSP1
OASIS PortalDUSP1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICDUSP1  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DDUSP1
Mutations and Diseases : HGMDDUSP1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch DUSP1
DgiDB (Drug Gene Interaction Database)DUSP1
DoCM (Curated mutations)DUSP1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)DUSP1 (select a term)
NCG5 (London)DUSP1
Cancer3DDUSP1(select the gene name)
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry DUSP1
NextProtP28562 [Medical]
Target ValidationDUSP1
Huge Navigator DUSP1 [HugePedia]
snp3D : Map Gene to Disease1843
BioCentury BCIQDUSP1
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD1843
Chemical/Pharm GKB GenePA27519
Clinical trialDUSP1
canSAR (ICR)DUSP1 (select the gene name)
DataMed IndexDUSP1
PubMed209 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Nov 13 21:16:01 CET 2019

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us